Selegiline (l-Deprenyl) as a Unique Neuroprotective Agent for Chronic Neurodegenerative Disorders- A Lesson from MAO Inhibition

Publisher： Bentham Science Publishers

E-ISSN： 1875-6158|4|4|255-267

ISSN： 1568-0150

Source： Current Medicinal Chemistry - Central Nervous System Agents, Vol.4, Iss.4, 2004-12, pp. : 255-267

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Efficacy of Selegiline in Neurodegenerative Disorders and Neurological Diseases

By  

Current Drug Targets, Vol. 7, Iss. 11, 2006-11 ,pp. : 1513-1529

Bentham Science Publishers

Access to resources Recommend Favorite

Metabolism of Selegiline [(-)-Deprenyl)]

By  

Current Medicinal Chemistry, Vol. 21, Iss. 13, 2014-04 ,pp. : 1522-1530

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration

By Castagnoli K.   Petzer J. B.   Steyn S. J.   Van Der Schyf C. J.   Castagnoli N.  

Inflammopharmacology, Vol. 11, Iss. 2, 2003-06 ,pp. : 183-188

VSP

Access to resources Recommend Favorite

Safety of Selegiline (Deprenyl) in the Treatment of Parkinson's Disease

By Heinonen E.H.  

Drug Safety, Vol. 19, Iss. 1, 1998-07 ,pp. : 11-22

Adis International

Access to resources Recommend Favorite

Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders

By  

Current Pharmaceutical Design, Vol. 16, Iss. 25, 2010-08 ,pp. : 2799-2817

Bentham Science Publishers

Access to resources Recommend Favorite